Literature DB >> 8305481

Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: structure, expression of cDNA in E. coli and enzymic properties.

T Pourmotabbed1, T L Solomon, K A Hasty, C L Mainardi.   

Abstract

Human neutrophils can be triggered to release the collagenolytic metalloenzymes, interstitial collagenase and 92 kDa type IV collagenase/gelatinase. We have isolated and sequenced a 2.3 kb cDNA from a chronic granulocytic leukemia cDNA library that encodes for human neutrophil type IV collagenase. With the exception of one amino-acid substitution at position 280 (Arg-->Gln), the deduced amino-acid sequences of neutrophil gelatinase are identical to the amino-acid sequences of the enzyme isolated from fibrosarcoma cells. Expression of the cDNA in E. coli yielded a 72 kDa protein having a gelatinolytic activity on zymogram gel. The recombinant enzyme was activated with APMA and trypsin. The activation was accompanied by a reduction in molecular weight of approximately 10 kDa; such a reduction is characteristic of matrix metalloproteinases. The recombinant gelatinase cleaved native type V and XI collagens. Native type I collagen was not a substrate for the enzyme. These data suggest that native and recombinant 92 kDa type IV collagenase produced in E. coli have similar biochemical properties. The successful expression of the collagenase in a prokaryotic system will greatly facilitate the structure-function characterization of the enzyme and allow a more precise analysis of its physiological and pathological roles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8305481     DOI: 10.1016/0167-4838(94)90038-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils.

Authors:  F Mollinedo; M Nakajima; A Llorens; E Barbosa; S Callejo; C Gajate; A Fabra
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 2.  Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites.

Authors:  Christopher M Overall
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

3.  Role of the conserved histidine and aspartic acid residues in activity and stabilization of human gelatinase B: an example of matrix metalloproteinases.

Authors:  T Pourmotabbed; J A Aelion; D Tyrrell; K A Hasty; C H Bu; C L Mainardi
Journal:  J Protein Chem       Date:  1995-10

4.  The distribution, clearance, and safety of an anti-MMP-9 DNAzyme in normal and MMTV-PyMT transgenic mice.

Authors:  Miranda A Hallett; Pooja Dalal; Trevor W Sweatman; Tayebeh Pourmotabbed
Journal:  Nucleic Acid Ther       Date:  2013-10-01       Impact factor: 5.486

5.  Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.

Authors:  Chun Gu; Fang Wang; Zhenwen Zhao; Hongyue Wang; Xiangfeng Cong; Xi Chen
Journal:  Front Physiol       Date:  2017-04-27       Impact factor: 4.566

6.  Expression of matrix metalloproteinase-9 in gingival tissue biopsy in patients with slowly/ moderately and rapidly progressing periodontitis: An observational study.

Authors:  Papita Ghosh; Thamil Selvan Muthuraj; Prasanta Bandyopadhyay; Snehasikta Swarnakar; Puja Sarkar; Abinaya Varatharajan
Journal:  J Indian Soc Periodontol       Date:  2021-08-30

7.  MMP9 SNP and MMP SNP-SNP interactions increase the risk for ischemic stroke in the Han Hakka population.

Authors:  Daofeng Fan; Chong Zheng; Wenbao Wu; Yinjuan Chen; Dongping Chen; Xiaohong Hu; Chaoxiong Shen; Mingsheng Chen; Rongtong Li; Yangui Chen
Journal:  Brain Behav       Date:  2022-01-05       Impact factor: 2.708

Review 8.  The Role of Matrix Metalloproteinase Polymorphisms in Ischemic Stroke.

Authors:  Jason J Chang; Ansley Stanfill; Tayebeh Pourmotabbed
Journal:  Int J Mol Sci       Date:  2016-08-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.